Hospira today announced that Inflectra (infliximab), the first monoclonal antibody (mAb) biosimilar therapy, has been registered in Australia. This registration paves the way for the Federal Government to reduce the cost of some of the most expensive medicines on the Pharmaceutical Benefits Scheme (PBS).
More...
Medical.net - Hospira announces TGA approval of Inflectra (infliximab) for treatment
More...
0 commentaires:
Enregistrer un commentaire